keyword
https://read.qxmd.com/read/38474036/transforming-growth-factor-beta-and-alveolar-rhabdomyosarcoma-a-challenge-of-tumor-differentiation-and-chemotherapy-response
#21
REVIEW
Bhavya Bhushan, Rosa Iranpour, Amirmohammad Eshtiaghi, Simone C da Silva Rosa, Benjamin W Lindsey, Joseph W Gordon, Saeid Ghavami
Alveolar rhabdomyosarcoma (ARMS), an invasive subtype of rhabdomyosarcoma (RMS), is associated with chromosomal translocation events resulting in one of two oncogenic fusion genes, PAX3-FOXO1 or PAX7-FOXO1 . ARMS patients exhibit an overexpression of the pleiotropic cytokine transforming growth factor beta (TGF-β). This overexpression of TGF-β1 causes an increased expression of a downstream transcription factor called SNAIL, which promotes epithelial to mesenchymal transition (EMT). Overexpression of TGF-β also inhibits myogenic differentiation, making ARMS patients highly resistant to chemotherapy...
February 28, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38456444/stroke-causes-dna-methylation-at-ncx1-heart-promoter-in-the-brain-via-dnmt1-mecp2-rest-epigenetic-complex
#22
JOURNAL ARTICLE
Natascia Guida, Angelo Serani, Luca Sanguigno, Luigi Mascolo, Ornella Cuomo, Salvatore Fioriniello, Domenico Marano, Floriana Della Ragione, Serenella Anzilotti, Paola Brancaccio, Pasquale Molinaro, Giuseppe Pignataro, Lucio Annunziato, Luigi Formisano
BACKGROUND: REST (Repressor-Element 1 [RE1]-silencing transcription factor) inhibits Na+ /Ca2+ exchanger-1 ( Ncx1 ) transcription in neurons through the binding of RE1 site on brain promoter (Br) after stroke. We identified a new putative RE1 site in Ncx1 heart promoter (Ht) sequence ( Ht -RE1) that participates in neuronal Ncx1 transcription. Because REST recruits DNA-methyltransferase-1 (DNMT1) and MeCP2 (methyl-CpG binding protein 2) on different neuronal genes, we investigated the role of this complex in Ncx1 transcriptional regulation after stroke...
March 8, 2024: Journal of the American Heart Association
https://read.qxmd.com/read/38453481/a-maternal-effect-padi6-variant-causes-nuclear-and-cytoplasmic-abnormalities-in-oocytes-as-well-as-failure-of-epigenetic-reprogramming-and-zygotic-genome-activation-in-embryos
#23
JOURNAL ARTICLE
Carlo Giaccari, Francesco Cecere, Lucia Argenziano, Angela Pagano, Antonio Galvao, Dario Acampora, Gianna Rossi, Bruno Hay Mele, Basilia Acurzio, Scott Coonrod, Maria Vittoria Cubellis, Flavia Cerrato, Simon Andrews, Sandra Cecconi, Gavin Kelsey, Andrea Riccio
Maternal inactivation of genes encoding components of the subcortical maternal complex (SCMC) and its associated member, PADI6, generally results in early embryo lethality. In humans, SCMC gene variants were found in the healthy mothers of children affected by multilocus imprinting disturbances (MLID). However, how the SCMC controls the DNA methylation required to regulate imprinting remains poorly defined. We generated a mouse line carrying a Padi6 missense variant that was identified in a family with Beckwith-Wiedemann syndrome and MLID...
March 7, 2024: Genes & Development
https://read.qxmd.com/read/38452757/a-2-week-treatment-with-5-azacytidine-improved-the-hypercontractility-state-in-prostate-from-obese-mice-role-of-the-nitric-oxide-cyclic-guanosine-monophosphate-signalling-pathway
#24
JOURNAL ARTICLE
Ana Carolina Ghezzi, Gabriela Reolon Passos, Mariana Gonçalves de Oliveira, Akila Lara Oliveira, Guilherme Rossi Assis-Mendonça, Glaucia Coelho de Mello, Edson Antunes, Fabiola Zakia Monica
Benign prostatic hyperplasia (BPH) is characterised by increases in prostate volume and contraction. Downregulation of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signalling pathway contributes to prostate dysfunctions. Previous studies in cancer cells or vessels have shown that the epigenetic mechanisms control the gene and protein expression of the enzymes involved in the production of NO and cGMP. This study is aimed to evaluate the effect of a 2-week treatment of 5-azacytidine (5-AZA), a DNA-methyltransferase inhibitor, in the prostate function of mice fed with a high-fat diet...
April 2024: Clinical and Experimental Pharmacology & Physiology
https://read.qxmd.com/read/38449958/successful-treatment-with-venetoclax-plus-azacytidine-combined-with-radiation-therapy-and-donor-lymphocyte-infusion-in-a-patient-with-extramedullary-relapse-of-acute-myeloid-leukemia-after-stem-cell-transplantation
#25
Shotaro Shirato, Satoshi Iyama, Akihito Fujimi, Satoshi Takahashi, Masayoshi Kobune
Extramedullary (EM) relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) is rare and causes systemic relapse. Consequently, the prognosis is very poor because limited treatment is feasible in post-transplant patients. The efficacy and safety of venetoclax (VEN), a newly developed oral inhibitor of B-cell leukemia/lymphoma-2, plus azacytidine (AZA) in patients newly diagnosed with AML who are ineligible for intensive chemotherapy have been reported. We report a case in which VEN + AZA salvage treatment following radiation therapy and donor lymphocyte infusion afforded promising results in a patient with AML who showed post-allo-HSCT EM relapse...
February 2024: Curēus
https://read.qxmd.com/read/38435958/improved-treatment-outcomes-with-modified-induction-therapy-in-acute-myeloid-leukemia-aml-a-retrospective-observational-study-from-a-regional-cancer-center
#26
JOURNAL ARTICLE
Asif Iqbal, Manas Dubey, Amritjot Singh Randhawa, Duncan Khanikar, Munlima Hazarika, Partha S Roy, Chayanika Dutta, Suhani Barbhuiyan, Roopam Deka
BACKGROUND: The aggressive, genetically diverse group of malignant illnesses known as acute myeloid leukemia (AML) is characterized by clonally related myeloblast invasion of the bone marrow, blood, and other organs. The treatment regimen plays a crucial role in the management of AML, and it is associated with poor overall survival and enhanced risk of relapse. Induction therapy with a 7+3 DA regimen (daunorubicin + ara-C) has been the treatment of choice for young and fit patients. OBJECTIVE: To evaluate the effect of dose modification in young and fit patients for a modified treatment regimen...
January 2024: Curēus
https://read.qxmd.com/read/38430306/successful-use-of-palbociclib-combined-with-venetoclax-and-azacitidine-in-an-adult-with-refractory-relapsed-therapy-related-acute-myeloid-leukemia
#27
JOURNAL ARTICLE
Wenqiang Qu, Jialing Lu, Yujie Ji, Zhewei He, Mengjia Hou, Dongyang Li, Yan Yang, Dan Liu, Suning Chen
BACKGROUND: Therapy-related acute myeloid leukemia (t-AML) is considered high risk as it related to prior exposure to cytotoxic chemotherapy agents for solid tumors or hematologic malignancies. Compared with de novo AML, t-AML is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. Many efforts have been devoted to improving the overall but with limited success, and novel strategy is thus highly needed. CASE DESCRIPTION: We reported one patient with refractory/relapsed t-AML was successfully treated with Palbociclib combined with Venetoclax and Azacytidine (AZA)...
March 2, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38423637/azacitidine-hesperetin-combination-induces-s-phase-cell-cycle-arrest-and-apoptosis-in-human-leukemia-cells
#28
JOURNAL ARTICLE
Kuan-Ming Lai, Ruo-Han Tseng, Yu-Hung Shih, Ying-Chih Huang
BACKGROUND/AIM: Chemotherapy drugs for leukemia, such as 5-azacytidine (Aza), have often various adverse effects. Hesperetin (Hes), a naturally occurring compound, is a potential adjuvant agent for anticancer therapy. This study aimed to investigate the effect of an Aza-Hes combination on acute leukemia cell lines, which elucidates the role of combination treatment in leukemia progression. MATERIALS AND METHODS: HL-60 and U937 cells were treated with Aza and Hes at various concentrations or their combination...
March 2024: Anticancer Research
https://read.qxmd.com/read/38413759/hypermethylated-genome-of-a-fish-vertebrate-iridovirus-isknv-plays-important-roles-in-viral-infection
#29
JOURNAL ARTICLE
Mincong Liang, Weiqiang Pan, Yanlin You, Xiaowei Qin, Hualong Su, Zhipeng Zhan, Shaoping Weng, Changjun Guo, Jianguo He
Iridoviruses are nucleocytoplasmic large dsDNA viruses that infect invertebrates and ectothermic vertebrates. The hypermethylated genome of vertebrate iridoviruses is unique among animal viruses. However, the map and function of iridovirus genomic methylation remain unknown. Herein, the methylated genome of Infectious spleen and kidney necrosis virus (ISKNV, a fish iridovirus), and its role in viral infection, are investigated. The methylation level of ISKNV is 23.44%. The hypermethylated genome is essential for ISKNV amplification, but there is no correlation between hypermethylation and viral gene expression...
February 28, 2024: Communications Biology
https://read.qxmd.com/read/38387931/-clinical-efficacy-of-hypomethylating-agent-therapy-in-patients-with-chronic-myelomonocytic-leukemia
#30
JOURNAL ARTICLE
Xiao Li, Yan Wang, Yu-Jie Guo, Zhi-Yun Niu, Li Ma, Xu-Quan Zhou, Jing-Yu Zhang
OBJECTIVE: To observe the clinical efficacy and safety of hypomethylating agent therapy in chronic myelomonocytic leukemia (CMML). METHODS: From February 2014 to June 2021, the clinical data, efficacy, survival time and safety of CMML patients diagnosed in the Second Hospital of Hebei Medical University and treated with hypomethylating agent therapy were retrospectively analyzed. RESULTS: A total of 25 CMML patients received hypomethylating agent therapy, including 18 cases treated with decitabine (DEC) and 7 cases treated with azacytidine (AZA) as the basic treatment...
February 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/38372898/targeted-crispr-activation-is-functional-in-engineered-human-pluripotent-stem-cells-but-undergoes-silencing-after-differentiation-into-cardiomyocytes-and-endothelium
#31
JOURNAL ARTICLE
Elaheh Karbassi, Ruby Padgett, Alessandro Bertero, Hans Reinecke, Jordan M Klaiman, Xiulan Yang, Stephen D Hauschka, Charles E Murry
Human induced pluripotent stem cells (hiPSCs) offer opportunities to study human biology where primary cell types are limited. CRISPR technology allows forward genetic screens using engineered Cas9-expressing cells. Here, we sought to generate a CRISPR activation (CRISPRa) hiPSC line to activate endogenous genes during pluripotency and differentiation. We first targeted catalytically inactive Cas9 fused to VP64, p65 and Rta activators (dCas9-VPR) regulated by the constitutive CAG promoter to the AAVS1 safe harbor site...
February 19, 2024: Cellular and Molecular Life Sciences: CMLS
https://read.qxmd.com/read/38372700/m6a-modification-regulates-tumor-suppressor-diras1-expression-in-cervical-cancer-cells
#32
JOURNAL ARTICLE
Yu-Yan Wang, Lian-Hua Ye, An-Qi Zhao, Wei-Ran Gao, Ning Dai, Yu Yin, Xin Zhang
DIRAS family GTPase 1 (DIRAS1) has been reported as a potential tumor suppressor in other human cancer. However, its expression pattern and role in cervical cancer remain unknown. Knockdown of DIRAS1 significantly promoted the proliferation, growth, migration, and invasion of C33A and SiHa cells cultured in vitro . Overexpression of DIRAS1 significantly inhibited the viability and motility of C33A and SiHa cells. Compared with normal cervical tissues, DIRAS1 mRNA levels were significantly lower in cervical cancer tissues...
December 31, 2024: Cancer Biology & Therapy
https://read.qxmd.com/read/38354740/slc25a51-decouples-the-mitochondrial-nad-nadh-ratio-to-control-proliferation-of-aml-cells
#33
JOURNAL ARTICLE
Mu-Jie Lu, Jonathan Busquets, Valeria Impedovo, Crystal N Wilson, Hsin-Ru Chan, Yu-Tai Chang, William Matsui, Stefano Tiziani, Xiaolu A Cambronne
SLC25A51 selectively imports oxidized NAD+ into the mitochondrial matrix and is required for sustaining cell respiration. We observed elevated expression of SLC25A51 that correlated with poorer outcomes in patients with acute myeloid leukemia (AML), and we sought to determine the role SLC25A51 may serve in this disease. We found that lowering SLC25A51 levels led to increased apoptosis and prolonged survival in orthotopic xenograft models. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from mitochondrial oxidative pathways, notably without increased glycolytic flux...
April 2, 2024: Cell Metabolism
https://read.qxmd.com/read/38345160/flow-cytometry-of-dnmt1-as-a-biomarker-of-hypomethylating-therapies
#34
JOURNAL ARTICLE
Philip G Woost, Basem M William, Brenda W Cooper, Masumi Ueda Oshima, Folashade Otegbeye, Marcos J De Lima, David Wald, Reda Z Mahfouz, Yogen Saunthararajah, Tammy Stefan, James W Jacobberger
The 5-azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation-inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid leukemias (AML), and under evaluation as maintenance therapy for AML postallogeneic hematopoietic stem cell transplant and to treat hemoglobinapathies. Malignant cell cytoreduction is thought to occur by S-phase specific depletion of the key epigenetic regulator, DNA methyltransferase 1 (DNMT1) that, in the case of cancers, thereby releases terminal-differentiation programs...
February 12, 2024: Cytometry. Part B, Clinical Cytometry
https://read.qxmd.com/read/38333211/case-report-cytopenias-in-vexas-syndrome-a-who-2022-based-approach-in-a-single-center-cohort
#35
Elisa Diral, Corrado Campochiaro, Alessandro Tomelleri, Gregorio M Bergonzi, Umberto Pizzano, Maurilio Ponzoni, Lucia Bongiovanni, Paola Ronchi, Cristina Tresoldi, Silvia Rigamonti, Federico Scarfò, Gloria M Latino, Emma Rinaldi, Massimo Bernardi, Lorenzo Dagna, Fabio Ciceri
VEXAS syndrome is an acquired autoinflammatory disease characterized in most cases by cytopenias and macrocytic anemia. Dyshematopoiesis is a frequent finding in chronic inflammatory conditions and therefore, cytopenias are not easily classified in VEXAS patients. Here we report a series of 7 patients affected by VEXAS associated cytopenias, treated at our center. The use of NGS, together with morphological assays, integrated with the WHO 2022 criteria, allowed to identify three subsets of VEXAS associated cytopenias: ICUS (idiopathic cytopenia of uncertain significance), CCUS (clonal cytopenia of uncertain significance) at high risk of clonal evolution, and MDS...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38330871/hypermethylation-of-pparg-encoding-gene-promoter-mediates-fine-particulate-matter-induced-pulmonary-fibrosis-by-regulating-the-hmgb1-nlrp3-axis
#36
JOURNAL ARTICLE
Siyu Yang, Yaochuan Sun, Yajun Luo, Yingyi Liu, Mengyu Jiang, Jiayou Li, Qibing Zhang, Jun Bai
The inflammatory response induced by fine particulate matter (PM2.5 ), a common class of air pollutants, is an important trigger for the development of pulmonary fibrosis. However, the specific mechanisms responsible for this phenomenon are yet to be fully understood. To investigate the mechanisms behind the onset and progression of lung fibrosis owing to PM2.5 exposure, both rats and human bronchial epithelial cells were subjected to varying concentrations of PM2.5 . The involvement of the PPARG/HMGB1/NLRP3 signaling pathway in developing lung fibrosis caused by PM2...
February 7, 2024: Ecotoxicology and Environmental Safety
https://read.qxmd.com/read/38302503/dna-demethylation-and-tri-methylation-of-h3k4-at-the-tacstd2-promoter-are-complementary-players-for-trop2-regulation-in-colorectal-cancer-cells
#37
JOURNAL ARTICLE
A Gehring, K Huebner, H Rani, K Erlenbach-Wuensch, S Merkel, V Mahadevan, R Grutzmann, A Hartmann, R Schneider-Stock
TROP2 is a powerful cancer driver in colorectal cancer cells. Divergent epigenetic regulation mechanisms for the corresponding TACSTD2 gene exist such as miRNAs or DNA methylation. However, the role of TACSTD2 promoter hypermethylation in colorectal cancer has not been investigated yet. In this study, TROP2 expression strongly correlated with promoter methylation in different colorectal tumor cell lines. Treatment with 5-Azacytidine, a DNMT1 inhibitor, led to demethylation of the TACSTD2 promoter accompanied by an increase in TROP2 protein expression...
February 1, 2024: Scientific Reports
https://read.qxmd.com/read/38285081/low-dose-venetoclax-combined-with-azacitidine-for-blastic-plasmacytoid-dendritic-cell-neoplasm-a-case-report-and-literature-review
#38
REVIEW
Qiuyan Wang, Yajing Zhao, Xiao Zang, Guizhi Zhou, Yongxia Liu, Qi Feng, Xin Li, Wen Wang, Xiaoyuan Dong, Xinguang Liu, Jun Peng, Chuanfang Liu
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that is highly aggressive with a poor prognosis. There is no standard treatment for BPDCN. Although conventional chemotherapies are usually sensitive in the initial therapy, relapse and drug resistance are inevitable within a short duration. Targeted therapies have enlightened new prospects for the treatment of BPDCN, especially for those in a frail state and intolerable to standard chemotherapies or hematopoietic stem cell transplantation...
March 2024: Annals of Hematology
https://read.qxmd.com/read/38262380/the-combination-of-shox2-and-rassf1a-dna-methylation-had-a-diagnostic-value-in-pulmonary-nodules-and-early-lung-cancer
#39
JOURNAL ARTICLE
Bin Xie, Wenyan Dong, Fengping He, Feng Peng, Honghua Zhang, Wei Wang
INTRODUCTION: The study explored the effects of SHOX2 and RASSF1A DNA methylation in lung cancer (LC). METHOD: Bronchoalveolar lavage fluid (BALF) samples as well as LC and normal adjacent tissues were collected from 72 LC patients and 35 patients with benign pulmonary nodules. Quantitative analysis of SHOX2 and RASSF1A DNA methylation was performed in benign pulmonary nodules and different stages of LC. The diagnostic value of SHOX2 and RASSF1A DNA methylation in LC and benign pulmonary nodules was determined by receiver operating characteristics analysis...
January 23, 2024: Oncology
https://read.qxmd.com/read/38212534/combining-venetoclax-and-azacytidine-with-t-cell-bispecific-antibodies-for-treatment-of-acute-myeloid-leukemia-a-preclinical-assessment
#40
JOURNAL ARTICLE
Gerulf Hänel, Anne Schönle, Anne-Sophie Neumann, Daniel Nixdorf, Nora Philipp, Monika Sponheimer, Alexandra Leutbecher, Alica-Joana Emhardt, Giulia Magno, Veit Bücklein, Jan Eckmann, Diana Dunshee, Vesna Kramar, Koorosh Korfi, Sara Colombetti, Pablo Umaña, Christian Klein, Marion Subklewe
No abstract text is available yet for this article.
January 11, 2024: Leukemia
keyword
keyword
21085
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.